 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
PFS results in TNBC
edit[1] (reporting on [2]) says "After a median follow-up of about 10 months ... The median PFS was 6.2 months with ipatasertib, compared with 4.9 months with placebo, for a hazard ratio (HR) of 0.60 (95% CI, 0.37–0.98; P = .037)." ... "The PFS difference appeared more pronounced in a prespecified analysis of patients with PIK3CA/AKT1/PTEN-altered tumors. In those patients, the median PFS was 9.0 months with ipatasertib compared with 4.9 months with placebo, for an HR of 0.44 (95% CI, 0.20–0.99; P = .041)." ... "A phase III trial in metastatic breast cancer is now underway..." - Rod57 (talk) 10:36, 27 August 2017 (UTC)